Identification of 1, 2, 5-Oxadiazoles as a New Class of SENP2 Inhibitors Using Structure Based Virtual Screening

Small ubiquitin like modifier (SUMO) specific proteases (SENPs) are cysteine proteases that carry out the proteolytic processing of SUMO from its pro form as well as the deconjugation of SUMO from substrate proteins. SENPs are attractive targets for drug discovery due to their crucial role in the development of various diseases. However, the SENPs inhibitor discovery efforts were limited, and only a few inhibitors or activity based probes have been identified until now. Here, we report a new class of SENP2 inhibitors identified by a combination of structure based virtual screening and quantitative FRET based assay. Our virtual screening protocol initially involves the identification of small molecules that have similar shape and electrostatic properties with the conjugate of SUMO1 C-terminal residues and substrate lysine. Molecular docking was then used to prioritize these small molecules for a FRET based assay that quantifies their SENP2 endopeptidase activity. The initial round of virtual screening followed by FRET based assay has enabled the identification of eight compounds with >40% SENP2 inhibition at 30 μM compound concentration. Five of these compounds belong to two scaffolds containing a 1,2,5-oxadiazole core that represent a novel class of SENP2 inhibitors. To improve the inhibitory potency and explore the structure-activity relationship of these two 1,2,5-oxadiazole scaffolds, structurally related compounds were identified in another round of virtual screening. The biological assay results confirmed SENP2 inhibitory activity of these two scaffolds. The most potent compound of each scaffold showed an IC50 of 5.9 and 3.7 μM. Most of the compounds also inhibited closely related isoform SENP1, while no detectable inhibition on other proteases, such as papain and trypsin, was observed. Our study suggests that 1,2,5-oxadiazoles could be used as a starting point for the development of novel therapeutic agents against various diseases targeting SENPs.

[1]  Yong Zuo,et al.  Small ubiquitin-like modifier protein-specific protease 1 and prostate cancer. , 2009, Asian journal of andrology.

[2]  Jinke Cheng,et al.  SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. , 2007, Cell.

[3]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[4]  Jaclyn R. Gareau,et al.  The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition , 2010, Nature Reviews Molecular Cell Biology.

[5]  Wei Hsu,et al.  SUMO-Specific Protease 2 Is Essential for Modulating p53-Mdm2 in Development of Trophoblast Stem Cell Niches and Lineages , 2008, PLoS biology.

[6]  Hitomi Yuki,et al.  Application of Support Vector Machine to Three-Dimensional Shape-Based Virtual Screening Using Comprehensive Three-Dimensional Molecular Shape Overlay with Known Inhibitors , 2012, J. Chem. Inf. Model..

[7]  Jie Li,et al.  SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors. , 2011, Cancer letters.

[8]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[9]  M. Dasso,et al.  Modification in reverse: the SUMO proteases. , 2007, Trends in biochemical sciences.

[10]  Wei Guo,et al.  Development of small-molecule inhibitors of Raf. , 2006, Recent patents on anti-infective drug discovery.

[11]  L. Lois,et al.  STRUCTURES OF THE SMALL UBIQUITIN-LIKE MODIFIER E1 ACTIVATING ENZYME PROVIDE INSIGHTS INTO SUMO ACTIVATION AND THE MECHANISM FOR E2 RECRUITMENT TO E1 , 2005 .

[12]  Guy S. Salvesen,et al.  Glycine Fluoromethylketones as SENP‐Specific Activity Based Probes , 2012, Chembiochem : a European journal of chemical biology.

[13]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[14]  Huo-Jian Shen,et al.  SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of β-catenin. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[15]  Derek S. Tan,et al.  Designed semisynthetic protein inhibitors of Ub/Ubl E1 activating enzymes. , 2010, Journal of the American Chemical Society.

[16]  Thomas A. Halgren,et al.  Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular. interactions , 1996, J. Comput. Chem..

[17]  C. Lima,et al.  Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1 , 2005, The EMBO journal.

[18]  Anthony Nicholls,et al.  Conformer Generation with OMEGA: Learning from the Data Set and the Analysis of Failures , 2012, J. Chem. Inf. Model..

[19]  D J Rogers,et al.  A Computer Program for Classifying Plants. , 1960, Science.

[20]  H. Ploegh,et al.  Specific and Covalent Targeting of Conjugating and Deconjugating Enzymes of Ubiquitin-Like Proteins , 2004, Molecular and Cellular Biology.

[21]  Christine Humblet,et al.  Computation of 3D queries for ROCS based virtual screens , 2009, J. Comput. Aided Mol. Des..

[22]  K. Sarge,et al.  Sumoylation and human disease pathogenesis. , 2009, Trends in biochemical sciences.

[23]  W. L. Jorgensen,et al.  The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. , 1988, Journal of the American Chemical Society.

[24]  Alexander M. Lewis,et al.  Identification of a chemical probe for NAADP by virtual screening , 2009, Nature chemical biology.

[25]  Benjamin A. Ellingson,et al.  Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..

[26]  Qingqing Meng,et al.  Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[27]  Simona Distinto,et al.  How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..

[28]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[29]  R. Hay,et al.  SUMO-specific proteases: a twist in the tail. , 2007, Trends in cell biology.

[30]  David Reverter,et al.  Structural basis for SENP2 protease interactions with SUMO precursors and conjugated substrates , 2006, Nature Structural &Molecular Biology.

[31]  Dima Kozakov,et al.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..

[32]  Pascal Reynier,et al.  Two-step differential expression analysis reveals a new set of genes involved in thyroid oncocytic tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[33]  Michael R. Kuehn,et al.  Mutation of SENP1/SuPr-2 Reveals an Essential Role for Desumoylation in Mouse Development , 2005, Molecular and Cellular Biology.

[34]  G. Salvesen,et al.  DeSUMOylating enzymes—SENPs , 2008, IUBMB life.

[35]  Jun Wang,et al.  Enhanced desumoylation in murine hearts by overexpressed SENP2 leads to congenital heart defects and cardiac dysfunction. , 2012, Journal of molecular and cellular cardiology.

[36]  Yang Song,et al.  Quantitative Förster resonance energy transfer analysis for kinetic determinations of SUMO-specific protease. , 2012, Analytical biochemistry.

[37]  Matthew Bogyo,et al.  Development of small molecule inhibitors and probes of human SUMO deconjugating proteases. , 2011, Chemistry & biology.

[38]  Bin Liu,et al.  2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: Virtual screening, synthesis and biological evaluation. , 2012, Bioorganic & medicinal chemistry letters.

[39]  Wim J. N. Meester,et al.  Small‐Molecule Inhibitors and Probes for Ubiquitin‐ and Ubiquitin‐Like‐Specific Proteases , 2005, Chembiochem : a European journal of chemical biology.

[40]  Steven Wong,et al.  Identification and characterization of a new chemotype of noncovalent SENP inhibitors. , 2013, ACS chemical biology.

[41]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[42]  M. Jiang,et al.  SUMO-specific protease 2 in Mdm2-mediated regulation of p53 , 2011, Cell Death and Differentiation.

[43]  E. Yeh,et al.  SUMOylation and De-SUMOylation: Wrestling with Life's Processes* , 2009, Journal of Biological Chemistry.

[44]  Heinrich Betz,et al.  Protein interactions in the sumoylation cascade – lessons from X‐ray structures , 2008, The FEBS journal.

[45]  Pengyu Ren,et al.  From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules. , 2012, ACS medicinal chemistry letters.

[46]  Jinke Cheng,et al.  Role of desumoylation in the development of prostate cancer. , 2006, Neoplasia.

[47]  Jinke Cheng,et al.  SENP1 Induces Prostatic Intraepithelial Neoplasia through Multiple Mechanisms* , 2010, The Journal of Biological Chemistry.

[48]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[49]  Derek S. Tan,et al.  Active site remodeling accompanies thioester bond formation in the SUMO E1 , 2009, Nature.

[50]  J. Zhao,et al.  Sumoylation regulates diverse biological processes , 2007, Cellular and Molecular Life Sciences.

[51]  Masaharu Uno,et al.  Discovery of 1-[4-(N-benzylamino)phenyl]-3-phenylurea derivatives as non-peptidic selective SUMO-sentrin specific protease (SENP)1 inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[52]  Pin-Chih Su,et al.  Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching. , 2012, Journal of medicinal chemistry.

[53]  Keigi Fujiwara,et al.  De-SUMOylation Enzyme of Sentrin/SUMO-Specific Protease 2 Regulates Disturbed Flow–Induced SUMOylation of ERK5 and p53 that Leads to Endothelial Dysfunction and Atherosclerosis , 2013, Circulation research.

[54]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[55]  Jinke Cheng,et al.  SUMO-Specific Protease 1 Is Essential for Stabilization of HIF1α during Hypoxia , 2007, Cell.